+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
566 locations
C

Actively Recruiting

Researchers are comparing two common hemodialysis methods, high-flux hemodialysis HD and hemodiafiltration HDF, to understand their effects on fatigue and recovery time after dialysis in patients aged 85 years and older. This randomized, multicenter, crossover trial aims to clarify which dialysis technique is better for older patients, as previous studies showed mixed results regarding recovery time with HDF in this age group. The study is designed to have each patient experience both treatments over separate periods for direct comparison. Participants will be randomly assigned to one of two sequences either three months of HD followed by three months of HDF or vice versa. Between these treatment periods, there will be two weeks of traditional low-flux hemodialysis to act as a washout. Treatments are administered three times a week, with sessions lasting 3.5 to 4 hours. Various dialysis parameters and medication details are recorded throughout the study to monitor the treatments. During the 7-month participation, patients will undergo multiple assessments including dialysis recovery time, fatigue levels using the SONG-fatigue scale, muscle performance via the stand-to-sit test, and quality of life through the SF-12 survey. Laboratory tests, blood pressure, and clinical events like hypotension and clotting are tracked regularly. Hospitalizations and mortality are also monitored to evaluate safety. Data are collected at screening, during both treatment periods, and follow-up visits, ensuring thorough monitoring of patient outcomes.

Age: 85Years +All GendersPhase Not Applicable
4 locations